BUFFALO, N.Y. and DURHAM, N.C., Jan. 7,
2016 /PRNewswire/ -- Albany Molecular Research Inc.
(NASDAQ: AMRI) and Icagen, Inc. announced today that they have
signed a collaboration agreement to co-market Icagen's ion channel
and transporter technology to global pharmaceutical and
biotechnology clients.
As part of the three-year agreement, AMRI clients and
customers gain access to Icagen's broad portfolio of assay tools
and technologies for ion channel and transporter research,
including their extensive collection of unique ion channel cell
lines and their proprietary XRpro® X-ray fluorescence technology
platform. Icagen's customers will benefit from AMRI's suite of
integrated drug discovery solutions, including expertise in
medicinal chemistry, in vitro DMPK assays, and computer-aided drug
discovery, as well as access to its proprietary ASCC small molecule
and natural products collections.
"We are excited to be entering into this collaboration with
Icagen as we look to provide drug discovery customers access to
unique cell lines and emerging technologies that complement our
service offerings," said Rory
Curtis, Ph.D., Vice President, Discovery Biology and
Pharmacology, and Site Head of AMRI Buffalo. "We anticipate that
Icagen's expertise in ion channel drug development and their
comprehensive portfolio of assay tools will be beneficial to AMRI's
drug discovery efforts."
"We are pleased to be able to provide our clients access to
AMRI's integrated chemistry services through this alliance," added
Richie Cunningham, Chief Executive
Officer of Icagen, Inc. "Icagen's ultimate goal is to reduce
the time and cost of bringing ion channel and transporter drug
candidates to market for our clients. AMRI's broad capabilities in
medicinal chemistry are expected to strengthen Icagen's ability to
efficiently advance our clients' drug candidates through
pre-clinical development."
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Solutions (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent, controlled substances, biologics, peptides, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
About Icagen, Inc.
Icagen partners with pharmaceutical
and biotechnology companies to offer industry-leading scientific
expertise and comprehensive access to technologies for ion channel
and transporter drug discovery and development. With over 20 years
of leadership in the ion channel field, the Icagen team offers an
extensive track record of success in advancing molecules from drug
discovery to clinical development across multiple therapeutic areas
and ion channel classes. Icagen's growing tool box comprises a
broad range of cell lines and technologies for ion channel and
transporter research, capped by the label-free XRpro®
platform. XRpro® technology, based on X-ray fluorescence, is
a novel method that enables high throughput assessment of ion
channels and transporters, including challenging systems with high
therapeutic interest. For more information on our company,
please visit our website at www.icagen.com.
Forward Looking Statements
This release
includes forward-looking statements on current expectations and
projections about future events of AMRI and Icagen. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions. These statements are based upon current beliefs,
expectations and assumptions and are subject to a number of risks
and uncertainties, many of which are difficult to predict and
include statements regarding benefits to be derived by AMRI and
Icagen from the collaboration. The forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those set forth or implied
by any forward-looking statements. Important factors that could
cause actual results to differ materially from those reflected in
the forward-looking statements include, among others, the ability
of AMRI and Icagen to successfully work together The information in
this release is provided only as of the date of this release, and
neither AMRI nor Icagen undertakes any obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-and-icagen-ink-collaboration-agreement-300201001.html
SOURCE AMRI; Icagen, Inc.